Welcome to Our Medtech Talk Podcast Channel

Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.

Renal Guard CEO Jim Dillon Discusses Spin Out of High Profile Reprieve Cardiovascular

October 15, 2018

Jim Dillon, president and CEO of Renal Guard, talks about the company’s decision to create Reprieve Cardiovascular, a start-up focusing on heart failure. Reprieve raised $7 million from outside investors, including Abiomed, and counts Serial Entrepreneur Howard Levin as chief medical officer.

Jim Dillon

CEO

Reprieve Cardiovascular

Jim Dillon started at RenalGuard Solutions in 2017. He recently launched Reprieve Cardiovascular, a new affiliated company solely focused on developing a unique therapy for Acutely Decompensated Heart Failure patients. Previously he held a series of increasingly responsible corporate strategic and sales leadership positions at St. Jude Medical. Within these roles, he drove market development and new technology adoption, executed capital/consumable sales strategies and built high-performance elite commercial teams. Mr. Dillon was also involved with multiple highly successful medical device companies including startups VNUS Medical Technologies, Perclose, Heart Technologies, and Devices for Vascular Intervention as a key contributor to their acquisition and exit, as well as providing prominent leadership related to both sales and business development. Prior to joining St. Jude, he also held senior executive sales and marketing positions with such companies as Abiomed, TherOx, and InfraReDx, where he was intimately involved with global clinical development and commercial distribution.